Results 81 to 90 of about 48,070 (253)
Introduction. Digoxin is used to control ventricular rate in atrial fibrillation (AF). There is conflicting evidence regarding safety of digoxin. We aimed to evaluate the risk of mortality with digoxin use in patients with AF using meta-analyses. Methods.
Surbhi Chamaria +4 more
doaj +1 more source
ABSTRACT These updated EAACI guidelines aim to standardize skin testing methodologies for both immediate and non‐immediate drug hypersensitivity reactions. For immediate reactions, the optimal testing window is 4–6 weeks post‐reaction; whereas beyond 6 months, false‐negative results increase.
Annick Barbaud +14 more
wiley +1 more source
Cardiac glycosides act through Na+/K+‐ATPase inhibition and downstream Ca2+/ROS signaling to induce immune remodeling and ferroptosis‐associated immunogenic cell death in multiple myeloma, thereby increasing sensitivity to antibody‐based therapies. ABSTRACT Although immunotherapies have improved outcomes in multiple myeloma (MM), therapeutic resistance
Tomoyuki Nakamura +14 more
wiley +1 more source
A Case of Digoxin Toxicity Due to Acute Renal Failure
Since the publication of the Digitalis Investigation Group trial in 1997, digoxin use has declined significantly. Medications such as angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) and beta-blockers that have been
Duke, Brandon +7 more
core +1 more source
Inhibition of P-glycoprotein–Mediated Efflux of Digoxin and Its Metabolites by Macrolide Antibiotics
This study was conducted to determine the rate of P-glycoprotein (P-gp)–mediated efflux of digoxin analogues and metabolites and to assess the effects of macrolide antibiotics on this efflux.
Jeff Hughes, Andrew Crowe
doaj +1 more source
Abstract Background Recent European Society of Clinical Microbiology and Infection and Australasian Society of Infectious Diseases Clostridioides difficile infection (CDI) management guidelines endorse the addition of intravenous tigecycline in patients who are progressing to fulminant infection.
Emma Bishop +5 more
wiley +1 more source
Digoxin-specific antibodies: a novel dosing strategy [PDF]
Digoxin-specific antibodies (digoxin-Fabs) are of value in the treatment of a strongly suspected or a known, potentially life-threatening digoxin toxicity. These antibodies are not registered for use in Europe; therefore Dutch hospital pharmacies are not
de Lange, Dylan W +7 more
core
Digoxin Immune Fab Administration following an Unexplained Increase in Serum Digoxin Concentration
Objective: To report a case of digoxin immune Fab (DIF) administration following an unexplained increase in serum digoxin concentration in an asymptomatic patient with chronic renal failure.
Augustine S. Aruna, Sandra G. Jue
core +1 more source
Abstract Background Evidence suggests that some medical emergencies in hospital are associated with preventable medication errors or adverse reactions. Aim The purpose of this case series was to investigate and describe the proportion of Medical Emergency Response Team (MERT) activations that are medication‐related, the degree of preventability and ...
Ian Coombes +9 more
wiley +1 more source
Contemporary Outcomes of Catheter Ablation of Long‐Standing Persistent Atrial Fibrillation
ABSTRACT Background Advances in mapping and ablation have improved the safety and efficacy of catheter‐based ablation (CA) of atrial fibrillation (AF). Patients with long‐standing persistent atrial fibrillation (LSPAF) historically have poor ablation outcomes; however, they are underrepresented in contemporary reports.
Dakota De Cecco +15 more
wiley +1 more source

